Prolotherapy Shows Edge Over Shock Wave Therapy for Chronic Plantar Fasciitis Pain
Head-to-head trial reveals prolotherapy provides better medium-term pain relief than shock wave therapy for stubborn heel pain.
Summary
Researchers compared two popular treatments for chronic plantar fasciitis in 70 patients over 12 weeks. Both prolotherapy (dextrose injections) and extracorporeal shock wave therapy (ESWT) significantly reduced morning pain and plantar fascia thickness. However, prolotherapy showed superior pain reduction at the 3-month mark, though functional improvements were similar between treatments. Both therapies required three sessions spaced two weeks apart, making them comparable time investments for patients seeking relief from this common heel condition.
Detailed Summary
Chronic plantar fasciitis affects millions, causing debilitating heel pain that can persist for months or years. This condition significantly impacts mobility and quality of life, making effective treatment crucial for maintaining active lifestyles as we age.
This randomized controlled trial compared two non-surgical treatments in 70 patients with chronic plantar fasciitis. The ESWT group received focused shock waves (1800-2000 pulses), while the prolotherapy group received 15% dextrose injections. Both treatments were administered in three sessions over six weeks.
Both treatments significantly reduced morning pain and plantar fascia thickness by 12 weeks. However, prolotherapy demonstrated superior overall pain reduction at the 3-month follow-up compared to ESWT. Functional improvements measured by foot and ankle ability scores were similar between groups.
These findings suggest prolotherapy may offer better medium-term pain management for chronic plantar fasciitis, though both treatments provide meaningful relief. For aging adults dealing with persistent heel pain, prolotherapy represents a promising minimally invasive option that could help maintain mobility and active lifestyles.
The study's 12-week follow-up period limits conclusions about long-term effectiveness, and larger studies would strengthen these preliminary findings.
Key Findings
- Both prolotherapy and ESWT significantly reduced morning pain and plantar fascia thickness
- Prolotherapy provided superior overall pain reduction at 3 months compared to ESWT
- Functional improvements were similar between both treatment groups
- Both treatments required three sessions spaced two weeks apart
- No significant differences in plantar pressure distribution between groups
Methodology
Randomized controlled trial of 70 patients comparing prolotherapy (15% dextrose injections) versus ESWT over 12 weeks. Outcomes measured included pain scores, foot function, plantar fascia thickness, and pressure distribution at baseline, 6 weeks, and 12 weeks.
Study Limitations
Study limited to 12-week follow-up period, preventing assessment of long-term effectiveness. Relatively small sample size and single-center design may limit generalizability of findings.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.